Sign In

Petra E.

Head of Strategic Pricing at AstraZeneca

Petra Sattler-Ermacora is an accomplished and highly experienced professional in the field of law, international relations, and diplomacy. She is a notable figure in the European Union and has served as a diplomat in prominent positions. She holds extensive knowledge in the areas of legal analysis, international law, negotiations, and dispute resolution. Petra has held various roles in the Industry such as the Director at the European External Action Service and has handled legal aspects of the EU's foreign and security policy. She has also worked as a lecturer and held visiting professorships at various universities. Furthermore, her presence is also acknowledged in various publications inclusive of her works on the law of the sea. Petra's expertise and work continue to gain widespread recognition in international affairs.

Highlights

Nov 16 · linkedin

Looking forward to presenting our poster on the topic of access to gene therapies in haemophilia at ISPOR Europe 2020 this week!

Take a look at our work using the following link: https://lnkd.in/dxaXqaU

PBI47: Innovative Approaches for Patient Access to Gene Therapies in Haemophilia

ISPOR—The Professional Society for Health Economics and Outcomes Research Dominika Mészárosová Andrea Denise O. David Carr

#ISPOReurope #ISPOReurope2020 #healthcare #health #genetherapy #genetherapies #haemophilia #hemophilia #healthtechnologyassessment #HTA

Jul 7 · linkedin

As a follow-up on my post on the Canadian Patented Medicines Regulations (PMR) that were planned to come into force this July, the Canadian PMPRB - Patented Medicine Prices Review Board announced that the amended PMR will now come into force on January 1, 2021. PMR were published in Canada Gazette II earlier in June, and Health Canada | Santé Canada has issued official confirmations of the delay - which may affect the access to treatments, including the new #COVID #vaccine. No other details are provided beyond an assurance that transitional measures will be sufficient to allow patentees to come into voluntary compliance with the guidelines. To find out more about the impact, below I am sharing the updated interview with Olaf Koester, MBA R.Ph., a former Canadian payer and a founding member of the pan-Canadian Pharmaceutical Alliance.

#canada #PMR #PMPRB #pharma #pharmaceuticalindustry #pharmaceuticals #HTA #pricing #reimbursement #marketaccess #healthcare #regulations

Related Questions

What is Petra Sattler-Ermacora's background in law and international relations?
How did Petra Sattler-Ermacora transition from law to strategic pricing at AstraZeneca?
What specific projects has Petra Sattler-Ermacora worked on at Precision Xtract?
What are Petra Sattler-Ermacora's key achievements in her career?
How long has Petra Sattler-Ermacora been at AstraZeneca?
Petra E.
Petra E., photo 1
Petra E., photo 2
Add to my network

Location

London, England, United Kingdom